Table 1. Characteristics of the patients... | American Society of Hematology

Table 1.

Characteristics of the patients at baseline

Patient no.	Age, y	Sex	WBC × 10⁹/L	Marrow blasts, %	CD19⁺ blasts percentage	Fusion proteins BCR-ABL	Mutations	CNS status∗	Time to achieve CR before CAR Ts, d	FTC dose† cells per kg	CART dose cells per kg	TKIs	TKIs duration	Time to last follow-up, mo	Status
1	52	Female	43	66	89	P190	Negative	1	10	5 × 10⁶	5 × 10⁶	Imatinib, Dasatinib	55	57	Alive in CR
2	58	Female	3	72	100	P190	Negative	1	9	5 × 10⁶	5 × 10⁶	Imatinib	54	55	Alive in CR
3	58	Female	19	65	90	P190	Negative	1	50	5 × 10⁶	5 × 10⁶	Imatinib	54	54	Alive in CR
4	33	Female	39	70	89	P210	ASXL1	1	40	5 × 10⁶	5 × 10⁶	Imatinib	25	25	Isolated CNS relapse, died
5	34	Female	47	50	96	P210	RUNX1, JAK1	1	48	5 × 10⁶	5 × 10⁶	Imatinib	55	55	Alive in CR
6	48	Female	81	81	96	P210	PAX5	1	37	3.25 × 10⁶	5 × 10⁶	Imatinib	28	30	Alive in CR
7	55	Male	88	95	93	P190	Negative	1	40	3.25 × 10⁶	5 × 10⁶	Imatinib	8	9	Withdrew due to fungal pneumonia
8	41	Male	88	84	99	P190	Negative	1	14	3.25 × 10⁶	5 × 10⁶	Imatinib	26	28	Alive in CR
9	38	Female	120	50	86	P210	RUNX1, STAT1	1	90	3.25 × 10⁶	5 × 10⁶	Dasatinib	21	24	Alive in CR
10	29	Female	128	86	96	P210	GATA1, SETD2	1	50	3.25 × 10⁶	5 × 10⁶	Imatinib	20	22	Alive in CR
11	41	Female	15	93	100	P190	KMT2C	1	21	2 × 10⁶	5 × 10⁶	Imatinib	24.5	27	Alive in CR
12	27	Female	7	80	96	P190	KMT2C	1	31	2 × 10⁶	5 × 10⁶	Imatinib	23.5	26	Alive in CR
13	51	Female	1	21	95	P190	Negative	1	80	2 × 10⁶	5 × 10⁶	Dasatinib	22	25	Alive in CR
14	34	Male	3	66	100	P190	ASXL1, TET2, BRCA2,EP300	1	50	2 × 10⁶	5 × 10⁶	Imatinib	22	24	Alive in CR
15	35	Female	34	63	92	P210	PDGFRB	1	58	2 × 10⁶	5 × 10⁶	Imatinib	7	7	Withdrew due to isolated CNS relapse

Patient no.	Age, y	Sex	WBC × 10⁹/L	Marrow blasts, %	CD19⁺ blasts percentage	Fusion proteins BCR-ABL	Mutations	CNS status∗	Time to achieve CR before CAR Ts, d	FTC dose† cells per kg	CART dose cells per kg	TKIs	TKIs duration	Time to last follow-up, mo	Status
1	52	Female	43	66	89	P190	Negative	1	10	5 × 10⁶	5 × 10⁶	Imatinib, Dasatinib	55	57	Alive in CR
2	58	Female	3	72	100	P190	Negative	1	9	5 × 10⁶	5 × 10⁶	Imatinib	54	55	Alive in CR
3	58	Female	19	65	90	P190	Negative	1	50	5 × 10⁶	5 × 10⁶	Imatinib	54	54	Alive in CR
4	33	Female	39	70	89	P210	ASXL1	1	40	5 × 10⁶	5 × 10⁶	Imatinib	25	25	Isolated CNS relapse, died
5	34	Female	47	50	96	P210	RUNX1, JAK1	1	48	5 × 10⁶	5 × 10⁶	Imatinib	55	55	Alive in CR
6	48	Female	81	81	96	P210	PAX5	1	37	3.25 × 10⁶	5 × 10⁶	Imatinib	28	30	Alive in CR
7	55	Male	88	95	93	P190	Negative	1	40	3.25 × 10⁶	5 × 10⁶	Imatinib	8	9	Withdrew due to fungal pneumonia
8	41	Male	88	84	99	P190	Negative	1	14	3.25 × 10⁶	5 × 10⁶	Imatinib	26	28	Alive in CR
9	38	Female	120	50	86	P210	RUNX1, STAT1	1	90	3.25 × 10⁶	5 × 10⁶	Dasatinib	21	24	Alive in CR
10	29	Female	128	86	96	P210	GATA1, SETD2	1	50	3.25 × 10⁶	5 × 10⁶	Imatinib	20	22	Alive in CR
11	41	Female	15	93	100	P190	KMT2C	1	21	2 × 10⁶	5 × 10⁶	Imatinib	24.5	27	Alive in CR
12	27	Female	7	80	96	P190	KMT2C	1	31	2 × 10⁶	5 × 10⁶	Imatinib	23.5	26	Alive in CR
13	51	Female	1	21	95	P190	Negative	1	80	2 × 10⁶	5 × 10⁶	Dasatinib	22	25	Alive in CR
14	34	Male	3	66	100	P190	ASXL1, TET2, BRCA2,EP300	1	50	2 × 10⁶	5 × 10⁶	Imatinib	22	24	Alive in CR
15	35	Female	34	63	92	P210	PDGFRB	1	58	2 × 10⁶	5 × 10⁶	Imatinib	7	7	Withdrew due to isolated CNS relapse

WBC, white blood cell.

∗

Classification of CNS status: CNS-1: no lymphoblasts in cerebrospinal fluid (CSF) regardless of the WBC count. CNS-2: WBC <5/mL in CSF with the presence of lymphoblasts. CNS-3: WBC ≥5/mL in CSF with the presence of lymphoblasts.

†

FTCs as a single dose at 5 × 10⁶ cells per kg, 3.25 × 10⁶ cells per kg, or 2 × 10⁶ cells per kg were administered on days 1 and 8, respectively.

View Large

This Feature Is Available To Subscribers Only